Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00623103




Registration number
NCT00623103
Ethics application status
Date submitted
14/02/2008
Date registered
25/02/2008
Date last updated
28/11/2011

Titles & IDs
Public title
Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)
Scientific title
A 76-week Prospective, Open-label, Multicenter Study to Evaluate the Long-term Effect of Rivastigmine Capsule and Transdermal Patch on Worsening of the Underlying Motor Symptoms of PD in Patients With Mild to Moderately Severe Dementia Associated With Parkinson's Disease (PDD)
Secondary ID [1] 0 0
CENA713B2315
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Parkinson's Disease Dementia 0 0
Condition category
Condition code
Neurological 0 0 0 0
Parkinson's disease
Neurological 0 0 0 0
Dementias
Neurological 0 0 0 0
Alzheimer's disease

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Rivastigmine capsule
Treatment: Drugs - Rivastigmine transdermal patch

Experimental: Rivastigmine capsule - Rivastigmine capsules starting at a total dose of 3 mg/day (1.5 mg twice daily orally) titrated up in 3 mg/day increments every 4 weeks to a final dose of 12 mg/day (6 mg twice daily orally). The 12 mg/day dose or the highest dose tolerated was maintained until week 76.

Experimental: Rivastigmine patch - Rivastigmine patch once a day in the morning, worn for 24 hours, starting at 5 cm\^2 (delivering 4.6 mg rivastigmine over a 24 hour period) for 4 weeks then titrated up to 10 cm\^2 daily (delivering 9.5 mg rivastigmine over a 24 hour period). The 10 cm\^2 patch or the highest well tolerated dose was maintained until week 76.


Treatment: Drugs: Rivastigmine capsule
Rivastigmine capsules orally twice a day. Target dose 12 mg/day.

Treatment: Drugs: Rivastigmine transdermal patch
Rivastigmine patch once a day in the morning, worn for 24 hours. Target dose 10 cm\^2/day delivering 9.5 mg over a 24 hour period.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage of Participants With Adverse Events (AEs) Due, or Potentially Due, to Worsening of Parkinson Disease (PD) Motor Symptoms (Tremor, Muscle Rigidity, Bradykinesia, Fall)
Timepoint [1] 0 0
76 Weeks
Primary outcome [2] 0 0
Percentage of Participants With Study Drug Discontinuations Due to Predefined AEs That Are Due, or Potentially Due, to Worsening of PD Motor Symptoms (Tremor, Muscle Rigidity, Bradykinesia, Fall)
Timepoint [2] 0 0
76 Weeks
Secondary outcome [1] 0 0
Change in Unified Parkinson Disease Rating Scale (UPDRS) Part III Motor Examination Scores at Weeks 8, 16, 24, 52 and 76 (or Early Discontinuation) Compared to Baseline
Timepoint [1] 0 0
From Baseline to Weeks 8, 16, 24, 52 and 76
Secondary outcome [2] 0 0
Change in Mattis Dementia Rating Scale (Mattis DRS-2) Scores at Weeks 16, 24, 52 and 76 Compared to Baseline
Timepoint [2] 0 0
From Baseline to Weeks 16, 24, 52 and 76
Secondary outcome [3] 0 0
Change in Ten Point Clock Test (TPCT) Scores at Weeks 16, 24, 52 and 76 (or Early Discontinuation) Compared to Baseline
Timepoint [3] 0 0
From Baseline to Weeks 16, 24, 52 and 76
Secondary outcome [4] 0 0
Change in Neuropsychiatric Inventory-10 (NPI-10) Scores at Weeks 16, 24, 52 and 76 (or Early Discontinuation) Compared to Baseline
Timepoint [4] 0 0
At Week 16, 24, 52 and 76 (or early discontinuation)
Secondary outcome [5] 0 0
Change in Alzheimer's Disease Cooperative Study-Activities Of Daily Living (ADCS-ADL) Scores at Weeks 16, 24, 52 and 76 (or Early Discontinuation) Compared to Baseline
Timepoint [5] 0 0
From Baseline to Week 16, 24, 52 and 76 (or early discontinuation)
Secondary outcome [6] 0 0
UPDRS Part V Stage (Modified Hoehn and Yahr Staging)at Baseline, Week 8,16,24,52 and 76 (or Early Discontinuation)
Timepoint [6] 0 0
From Baseline to Week 8, 16, 24, 52 and 76 (or early discontinuation)

Eligibility
Key inclusion criteria
* Diagnosis of idiopathic Parkinson's disease, according to the UK Parkinson's disease Society Brain Bank criteria
* Diagnosis of Parkinson's disease dementia according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria, with onset of symptoms of dementia at least 2 years following the first diagnosis of idiopathic Parkinson's disease
* Mini Mental State Examination score of =10 and = 26 (at Screening Visit only)
Minimum age
50 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* An advanced, severe, or unstable disease of any type that may interfere with the primary and secondary variable evaluations
* A score of 5 (wheelchair bound or bedridden) in the "on"-state on the Modified Hoehn and Yahr Staging (UPDRS Part V)
* A current diagnosis of any primary neurodegenerative disorder other than idiopathic PD
* A current diagnosis of any treatable dementia (hypothyroidism, syphilis, vitamin B12 or folate deficiency) that is verified by the investigator to be the cause of dementia.
* A current diagnosis of probably vascular dementia according to the National Institute of Neurological Disorders and Stroke and the Association International pour la Recherche et l'Enseignement en Neurosciences (NINDS-AIREN) criteria
* A current diagnosis of a major depressive episode according to DSM-IV criteria
* A history of stereotaxic brain surgery for Parkinson's disease
* A known exaggerated pharmacological sensitivity or hypersensitivity to drugs similar to rivastigmine or to other cholinergic compounds

Other protocol-defined inclusion/exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/01/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
583
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Novartis Investigative Site - Kogarah
Recruitment hospital [2] 0 0
Novartis Investigative Site - Heidelberg
Recruitment hospital [3] 0 0
Novartis Investigative Site - Malvern
Recruitment hospital [4] 0 0
Novartis Investigative Site - Melbourne
Recruitment hospital [5] 0 0
Novartis Investigative Site - Prahran
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
3084 - Heidelberg
Recruitment postcode(s) [3] 0 0
3144 - Malvern
Recruitment postcode(s) [4] 0 0
3050 - Melbourne
Recruitment postcode(s) [5] 0 0
3181 - Prahran
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Idaho
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Kansas
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Ohio
Country [11] 0 0
United States of America
State/province [11] 0 0
Pennsylvania
Country [12] 0 0
United States of America
State/province [12] 0 0
Texas
Country [13] 0 0
United States of America
State/province [13] 0 0
Utah
Country [14] 0 0
United States of America
State/province [14] 0 0
Washington
Country [15] 0 0
Argentina
State/province [15] 0 0
Buenos Aires
Country [16] 0 0
Argentina
State/province [16] 0 0
Capital Federal
Country [17] 0 0
Argentina
State/province [17] 0 0
Santa Fe
Country [18] 0 0
Austria
State/province [18] 0 0
Graz
Country [19] 0 0
Austria
State/province [19] 0 0
Innsbruck
Country [20] 0 0
Austria
State/province [20] 0 0
Linz
Country [21] 0 0
Austria
State/province [21] 0 0
Vienna
Country [22] 0 0
Belgium
State/province [22] 0 0
Antwerpen
Country [23] 0 0
Belgium
State/province [23] 0 0
Bruxelles
Country [24] 0 0
Belgium
State/province [24] 0 0
Edegem
Country [25] 0 0
Belgium
State/province [25] 0 0
Jette
Country [26] 0 0
Belgium
State/province [26] 0 0
Kortrijk
Country [27] 0 0
Belgium
State/province [27] 0 0
Leuven
Country [28] 0 0
Belgium
State/province [28] 0 0
Liege
Country [29] 0 0
Belgium
State/province [29] 0 0
Wilrijk
Country [30] 0 0
Canada
State/province [30] 0 0
Alberta
Country [31] 0 0
Canada
State/province [31] 0 0
British Columbia
Country [32] 0 0
Canada
State/province [32] 0 0
Nova Scotia
Country [33] 0 0
Canada
State/province [33] 0 0
Ontario
Country [34] 0 0
Canada
State/province [34] 0 0
Quebec
Country [35] 0 0
Canada
State/province [35] 0 0
Saskatchewan
Country [36] 0 0
France
State/province [36] 0 0
Amiens Cedex
Country [37] 0 0
France
State/province [37] 0 0
Clermont
Country [38] 0 0
France
State/province [38] 0 0
Lille Cedex
Country [39] 0 0
France
State/province [39] 0 0
Marseille Cedex
Country [40] 0 0
France
State/province [40] 0 0
Montpellier Cedex 5
Country [41] 0 0
France
State/province [41] 0 0
Paris Cedex
Country [42] 0 0
France
State/province [42] 0 0
Pessac Cedex
Country [43] 0 0
France
State/province [43] 0 0
Rennes
Country [44] 0 0
France
State/province [44] 0 0
Roanne
Country [45] 0 0
Germany
State/province [45] 0 0
Bad Nauheim
Country [46] 0 0
Germany
State/province [46] 0 0
Beelitz-Heilstaetten
Country [47] 0 0
Germany
State/province [47] 0 0
Berlin
Country [48] 0 0
Germany
State/province [48] 0 0
Bonn
Country [49] 0 0
Germany
State/province [49] 0 0
Dresden
Country [50] 0 0
Germany
State/province [50] 0 0
Goettingen
Country [51] 0 0
Germany
State/province [51] 0 0
Hamburg
Country [52] 0 0
Germany
State/province [52] 0 0
Kassel
Country [53] 0 0
Germany
State/province [53] 0 0
Leipzig
Country [54] 0 0
Germany
State/province [54] 0 0
Leun-Biskirchen
Country [55] 0 0
Germany
State/province [55] 0 0
Luebben
Country [56] 0 0
Germany
State/province [56] 0 0
Mainz
Country [57] 0 0
Germany
State/province [57] 0 0
Marburg
Country [58] 0 0
Germany
State/province [58] 0 0
Muenchen
Country [59] 0 0
Germany
State/province [59] 0 0
Munchen
Country [60] 0 0
Germany
State/province [60] 0 0
Nuernberg
Country [61] 0 0
Germany
State/province [61] 0 0
Ulm
Country [62] 0 0
Germany
State/province [62] 0 0
Wolfach
Country [63] 0 0
Italy
State/province [63] 0 0
BA
Country [64] 0 0
Italy
State/province [64] 0 0
BO
Country [65] 0 0
Italy
State/province [65] 0 0
BS
Country [66] 0 0
Italy
State/province [66] 0 0
FG
Country [67] 0 0
Italy
State/province [67] 0 0
IS
Country [68] 0 0
Italy
State/province [68] 0 0
LU
Country [69] 0 0
Italy
State/province [69] 0 0
MI
Country [70] 0 0
Italy
State/province [70] 0 0
RM
Country [71] 0 0
Italy
State/province [71] 0 0
TS
Country [72] 0 0
Italy
State/province [72] 0 0
VI
Country [73] 0 0
Italy
State/province [73] 0 0
Cassino
Country [74] 0 0
Italy
State/province [74] 0 0
Napoli
Country [75] 0 0
Netherlands
State/province [75] 0 0
AB
Country [76] 0 0
Netherlands
State/province [76] 0 0
AN
Country [77] 0 0
Netherlands
State/province [77] 0 0
AZ
Country [78] 0 0
Netherlands
State/province [78] 0 0
CK
Country [79] 0 0
Netherlands
State/province [79] 0 0
ER
Country [80] 0 0
Netherlands
State/province [80] 0 0
GC
Country [81] 0 0
Netherlands
State/province [81] 0 0
GZ
Country [82] 0 0
Netherlands
State/province [82] 0 0
JL
Country [83] 0 0
Netherlands
State/province [83] 0 0
PC
Country [84] 0 0
Netherlands
State/province [84] 0 0
Sittard
Country [85] 0 0
Spain
State/province [85] 0 0
Barcelona
Country [86] 0 0
Spain
State/province [86] 0 0
Madrid
Country [87] 0 0
Turkey
State/province [87] 0 0
Adana
Country [88] 0 0
Turkey
State/province [88] 0 0
Antalya
Country [89] 0 0
Turkey
State/province [89] 0 0
Istanbul
Country [90] 0 0
Turkey
State/province [90] 0 0
Izmir
Country [91] 0 0
Turkey
State/province [91] 0 0
Kocaeli
Country [92] 0 0
Turkey
State/province [92] 0 0
Sihhiye/Ankara
Country [93] 0 0
Turkey
State/province [93] 0 0
Yenisehir/Izmir
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Blackburn
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Blandford Forum, Dorset
Country [96] 0 0
United Kingdom
State/province [96] 0 0
Christchurch, Dorset
Country [97] 0 0
United Kingdom
State/province [97] 0 0
Newcastle
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Oxford
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Peterborough
Country [100] 0 0
United Kingdom
State/province [100] 0 0
Southampton
Country [101] 0 0
United Kingdom
State/province [101] 0 0
Vale of Glamorgan

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to provide long-term safety data for rivastigmine capsule and transdermal patch treatments, in particular the effect of rivastigmine on worsening of the underlying motor symptoms of Parkinson's Disease (PD), in patients with mild to moderately severe dementia associated with PD.
Trial website
https://clinicaltrials.gov/study/NCT00623103
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Novartis Pharmaceuticals
Address 0 0
Novartis Pharmaceuticals
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT00623103